CompletedPhase 2NCT01668537
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Studying OBSOLETE: Small pox
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Principal Investigator
- Richard N Greenberg, MDUniversity of Kentucky
- Intervention
- LF formulation of IMVAMUNE®(biological)
- Enrollment
- 651 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2013 – 2014
Study locations (3)
- Miami Research Associates, South Miami, Florida, United States
- PRA, Lenexa, Kansas, United States
- University of Kentucky, Lexington, Kentucky, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01668537 on ClinicalTrials.gov